Alnylam | pharmaphorum

Skip to main content

Sunday 14 December 2025

BlueSky linkedin youtube

header links

Get Newsletters
Media Kit

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
Spotlight on
Events

close

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

youtube linkedin BlueSky

Alnylam

News

Alnylam

Alnylam soars after drug success, paving way for RNAi era

Shares in US biotech Alnylam have soared after a late-stage study of its RNA interference drug patisaran met its primary endpoint.

News

Alnylam

Alnylam halts trials of haemophilia drug after patient death

Trials will resume once safety protocols have been reviewed.

News

DNA sequence

Silence Therapeutics takes rival Alnylam to court in patent ...

Silence claims late-stage drugs infringe patents.

News

Neuron_in_tissue_culture

Ionis hit by safety concerns, rivals Alnylam benefit

Biotech insists drug for rare inherited disorder is still approvable.

News

Alnylam

Alnylam plunges after deaths in rare disease trial

Biotech axes revusiran due to safety concerns.

News

Alnylam

Alnylam a ‘premier league’ addition to UK biotech

UK base will be operational HQ, Switzerland to be official head office

Load more results

Editor's Picks

UK and US agree zero tariffs on pharma – with price rises

FDA clears trial of 'vectorised' ALS antibody from VectorY

Tracy Beth Hoeg will be fifth CDER head this year

FDA takes steps to limit non-human primate testing

FDA could hike user fees for ex-US drug programmes

News

CHMP decision levels the playing field for GSK's RSV jab

CHMP decision levels the playing field for GSK's RSV jab

GSK's RSV vaccine is poised for EU approval in all adults aged 18 and over, bringing it into line with rival shots from Pfizer and Moderna.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Physicians walking and using tablet devices

Sponsored

How to meet your physicians where they are online

A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Get Newsletters

youtube linkedin BlueSky

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2025, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2025, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company